Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: Results from a single-institutional analysis

Combination therapy with gemcitabine and docetaxel has been reported to be a good therapeutic strategy for patients with soft tissue sarcoma. The aim of the present study was to analyze the efficacy and toxicity of gemcitabine with docetaxel in Japanese patients with advanced bone and soft tissue sa...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2017-05, Vol.12 (5), p.e0176972-e0176972
Main Authors: Takahashi, Masanobu, Komine, Keigo, Imai, Hiroo, Okada, Yoshinari, Saijo, Ken, Takahashi, Masahiro, Shirota, Hidekazu, Ohori, Hisatsugu, Takahashi, Shin, Chiba, Natsuko, Mori, Takahiro, Shimodaira, Hideki, Ishioka, Chikashi
Format: Article
Language:English
Subjects:
Adolescents
Adult
Adults
Aged
Aged, 80 and over
Aging
Analysis
Antimetabolites, Antineoplastic - adverse effects
Antimetabolites, Antineoplastic - therapeutic use
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Bevacizumab
Biocompatibility
Biology and Life Sciences
Biomedical materials
Bone cancer
Bone Neoplasms - drug therapy
Bone Neoplasms - mortality
Bone Neoplasms - pathology
Bone tumors
Cancer
Cancer therapies
Chemotherapy
Children
Chondrosarcoma
Curing
Cytotoxic agents
Cytotoxicity
Dacarbazine
Deoxycytidine - adverse effects
Deoxycytidine - analogs & derivatives
Deoxycytidine - therapeutic use
Disease-Free Survival
Docetaxel
Dosage and administration
Doxorubicin
Drug Administration Schedule
Drug therapy
Drug Therapy, Combination
Drugs
Effectiveness
Endometrium
Epirubicin
Ewing's sarcoma
Ewings sarcoma
Extremities
Feasibility studies
Female
Gemcitabine
Growth factors
Head
Head and neck
Hospitals
Humans
Japan
Male
Medicine and Health Sciences
Mesenchyme
Metastases
Metastasis
Middle Aged
Neoplasm Recurrence, Local - drug therapy
Neoplasm Recurrence, Local - mortality
Neoplasm Recurrence, Local - pathology
Neutropenia - chemically induced
Oncology
Organs
Patients
Quality
Radiation therapy
Retrospective Studies
Safety
Safety and security measures
Sarcoma
Sarcoma - drug therapy
Sarcoma - mortality
Sarcoma - pathology
Shrinkage
Soft Tissue Neoplasms - drug therapy
Soft Tissue Neoplasms - mortality
Soft Tissue Neoplasms - pathology
Stellar mass
Surgery
Survival
Survival Rate
Taxoids - adverse effects
Taxoids - therapeutic use
Tissues
Translocation
Treatment Outcome
Tumors
Tyrosine
Uterus
Vascular endothelial growth factor
Young Adult
Young adults
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Combination therapy with gemcitabine and docetaxel has been reported to be a good therapeutic strategy for patients with soft tissue sarcoma. The aim of the present study was to analyze the efficacy and toxicity of gemcitabine with docetaxel in Japanese patients with advanced bone and soft tissue sarcoma. We retrospectively analyzed the effect of gemcitabine and docetaxel therapy on overall response, progression-free survival, overall survival, and toxicity in 42 patients with bone or soft tissue sarcoma who had received the therapy between October 2006 and September 2015, at Tohoku University Hospital. The median age was 55 years; 23 patients were men, and 19 were women. Eight had bone sarcoma and 34 had soft tissue sarcoma. Forty patients (95%) had previously been treated with one or more chemotherapeutic regimens. The overall response rate was 6.9% and the disease control rate was 55%. The median progression-free survival was 2.3 months and the median overall survival was 14.3 months. Grade 3 or more neutropenia and febrile neutropenia were observed in 74% and 4.8% of all patients, respectively. The response rate was lower and myelosuppression was more frequently observed than in other previous reports. On the other hand, most of toxicities were enough manageable. In addition, some patients had long survival with a good response. Our study supports the notion that gemcitabine and docetaxel therapy is a good therapeutic option for treating patients with advanced soft tissue sarcoma as well as bone sarcoma, also in Asian populations.
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0176972